GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » GF Value Rank

Biosyent (Biosyent) GF Value Rank : 7 (As of May. 02, 2024)


View and export this data going back to . Start your Free Trial

What is Biosyent GF Value Rank?

Biosyent has the GF Value Rank of 7.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Competitive Comparison of Biosyent's GF Value Rank

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent's GF Value Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Biosyent's GF Value Rank falls into.



Biosyent GF Value Rank Related Terms

Thank you for viewing the detailed overview of Biosyent's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent (Biosyent) Business Description

Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.

Biosyent (Biosyent) Headlines

From GuruFocus

BioSyent Declares Second Quarter 2023 Dividend

By GlobeNewswire GlobeNewswire 05-25-2023

BioSyent Initiates First Dividend

By GlobeNewswire GlobeNewswire 10-12-2022

BioSyent to Present at Upcoming Investor Conferences

By GlobeNewswire GlobeNewswire 04-25-2018

BioSyent Announces Approval of New Product

By GlobeNewswire GlobeNewswire 05-31-2023

BioSyent Announces Grant of Restricted Share Units

By GlobeNewswire GlobeNewswire 03-31-2023

BioSyent Schedules Q2 and H1 2022 Earnings Release for August 23, 2022

By GlobeNewswire GlobeNewswire 08-17-2022

When Being Certain Isn't Enough

By Thomas Macpherson Thomas Macpherson 08-30-2019

BioSyent Announces Changes to Executive Management

By GlobeNewswire GlobeNewswire 09-10-2018

BioSyent Announces Adoption of Restricted Share Unit Plan

By GlobeNewswire GlobeNewswire 03-06-2020